What Does GIP Stand For and What Does It Do?

GIP stands for glucose-dependent insulinotropic polypeptide, a gut hormone released after you eat that helps your body manage blood sugar, store fat, and regulate appetite. It was originally called gastric inhibitory polypeptide when researchers first isolated it in the late 1960s, because they thought its main job was suppressing stomach acid. Once scientists realized it had a far bigger role in triggering insulin release, the name was updated to reflect that function, though the abbreviation stayed the same.

Two Names, One Hormone

The naming history of GIP tells you something about how science catches up with itself. Researchers originally purified GIP from crude gut-hormone preparations while looking for substances that inhibited gastric acid secretion. That function earned it the name gastric inhibitory polypeptide. But it soon became clear that GIP’s ability to boost insulin secretion after a meal was far more physiologically significant than its modest effects on stomach acid. The hormone was renamed glucose-dependent insulinotropic polypeptide to capture that role, while keeping the convenient three-letter abbreviation everyone already used.¹ You will still see both full names in textbooks and papers, and both are technically correct, but the newer name better describes what GIP actually does day to day.

Where GIP Comes From

GIP is produced by specialized cells called K-cells that line the walls of your upper small intestine. When food arrives in the gut, K-cells detect nutrients in the surrounding fluid and respond by releasing GIP into the bloodstream. The signal scales with what you eat: the type and amount of nutrients determine how much GIP gets pumped out.² Fasting levels of GIP in healthy people hover in a low range, but after a meal, concentrations can rise several-fold within half an hour. Mixed meals that contain carbohydrates, protein, and fat produce the strongest GIP response. Protein appears to trigger a faster and more robust GIP spike than fat, though both nutrients stimulate release.³

The Incretin Effect

GIP’s headline job is what endocrinologists call the incretin effect. When you eat and your blood sugar starts to rise, GIP travels to the pancreas and signals beta cells to release more insulin than blood sugar alone would trigger. This is why swallowing glucose produces a bigger insulin response than receiving the same amount of glucose intravenously: the gut hormones amplify the signal. GIP shares this incretin duty with another gut hormone, GLP-1 (glucagon-like peptide-1). The two together account for most of the incretin effect in healthy people, and their contributions are roughly additive.⁴

Which hormone does more of the heavy lifting depends on how you measure it. Studies using receptor-blocking drugs suggest GIP may be quantitatively the more important of the two for stimulating insulin, while GLP-1 contributes more by suppressing glucagon, the hormone that raises blood sugar.⁴ Other experiments that directly infuse each hormone at physiological glucose levels conclude the two contribute nearly equally, because their differences in blood concentration and potency roughly cancel each other out.⁵ Either way, GIP is clearly not a minor player. It is at least an equal partner with GLP-1 in keeping blood sugar stable after meals.

How GIP Gets Broken Down So Quickly

GIP’s active life in the bloodstream is strikingly short. An enzyme called DPP-4, which circulates in the blood and sits on cell surfaces throughout the body, clips two amino acids off the front end of the GIP molecule. That truncated fragment, GIP(3-42), is biologically inactive and cannot stimulate insulin release.⁶ Animal studies have shown that over half of infused GIP is converted to this inactive form within just two minutes.⁷ DPP-4 chews through GLP-1 the same way, which is why both incretins are fleeting signals. This rapid degradation is the reason DPP-4 inhibitor drugs (like sitagliptin) work: by blocking the enzyme, they keep both GIP and GLP-1 active longer, enhancing insulin secretion after meals.⁸

The rapid breakdown also creates headaches for researchers trying to measure GIP in blood samples. Once blood is drawn, DPP-4 keeps working in the tube, converting active GIP to the inactive fragment. Standard immunoassay kits often cannot distinguish between the two forms, which means they overestimate how much functional GIP was actually present.⁹ Newer mass-spectrometry-based methods have been developed to separately quantify the active and inactive forms, but they require specialized equipment and careful sample handling.¹⁰

GIP’s Role in Fat Storage

GIP does not just affect the pancreas. It has a direct line to fat tissue, and this is where its reputation gets complicated. In adipose tissue, GIP promotes the incorporation of fatty acids into triglycerides, stimulates fatty acid synthesis, boosts the sensitivity of fat cells to insulin, and increases the activity of lipoprotein lipase, an enzyme that pulls fat out of the bloodstream for storage.¹¹ In other words, GIP helps your body tuck dietary fat away into fat cells after a meal. This is part of normal metabolic housekeeping: after you eat a fatty meal, circulating fat needs to go somewhere safe, and GIP helps direct it into adipose tissue rather than letting it accumulate in blood vessels or the liver.

Human studies confirm that GIP infusions consistently reduce circulating free fatty acids, supporting the idea that GIP pushes fat into storage.¹² More recent work frames this as a beneficial process: by helping fat cells store lipids in a healthy, insulin-sensitive way, GIP may actually prevent the metabolic dysfunction that comes when fat overflows into the wrong tissues.¹³ This is a nuance that gets lost in popular accounts. GIP’s fat-storing action sounds like it should make you gain weight, and for years that was exactly how researchers interpreted it. The reality is more layered, as the next sections make clear.

GIP in the Brain

One of the more surprising discoveries of the past decade is that GIP receptors are scattered across brain regions involved in appetite and energy balance. They show up in the hypothalamus, which governs hunger and satiety, and in hindbrain areas like the area postrema and nucleus of the solitary tract, which process gut signals and regulate nausea.¹⁴ When long-acting GIP analogs are given to animals, neurons in these feeding centers become activated, and the animals eat less and lose weight.¹⁵

This brain activity adds a dimension to GIP’s role that was not appreciated for most of its history. The hormone is not just a peripheral signal between gut and pancreas. It also talks directly to the central nervous system, adjusting how hungry you feel and how much energy your body burns. Both GIP and GLP-1 receptors are expressed in overlapping brain feeding centers, which is part of why drugs targeting both receptors at once have such pronounced effects on weight.¹⁶

What GIP Does to Glucagon

GIP and GLP-1 handle the other major pancreatic hormone, glucagon, in opposite ways. GLP-1 suppresses glucagon, which helps keep blood sugar from rising too high after a meal. GIP, by contrast, stimulates glucagon release, but it does so in a glucose-dependent manner: the effect is strongest when blood sugar is low and fades as glucose rises.¹⁷ This means GIP may serve as a safety valve during fasting or between meals, nudging glucagon up to prevent blood sugar from dropping too far. It is a clever bit of biochemical design: the same hormone that amplifies insulin when glucose is high can push glucagon in the other direction when glucose is low.

Effects on Bone

GIP receptors are not confined to the pancreas, fat, and brain. They also appear on bone cells. Research on human bone cells shows that GIP slows down the activity of osteoclasts (cells that break bone down) and improves the survival of osteoblasts (cells that build bone up).¹⁸ This dual action suggests that GIP helps maintain bone density after meals, when nutrients are available for building and repairing bone. Reviews of gut-hormone effects on bone have confirmed that while GLP-1 and a related peptide GLP-2 also inhibit bone breakdown, GIP stands out for actively promoting bone formation as well.¹⁹ Whether this translates into a meaningful clinical benefit for osteoporosis remains to be seen, but it helps explain why people who skip meals or have gut conditions that impair hormone release sometimes develop weakened bones.

GIP Resistance in Type 2 Diabetes

In people with type 2 diabetes, GIP stops working as well. Beta cells become less responsive to the hormone, a phenomenon researchers call GIP resistance. Animal models of type 2 diabetes show that chronic high blood sugar causes the GIP receptor on beta cells to be downregulated, meaning fewer receptors are available to respond to the signal.²⁰ The encouraging side of this finding is that bringing blood sugar under control can reverse the receptor loss, at least in rodents. GIP resistance is one reason early diabetes drugs focused almost entirely on GLP-1 rather than GIP: if the GIP signal is broken in the very people you want to treat, targeting it seemed futile. That thinking has shifted dramatically with the development of dual-agonist drugs.

Tirzepatide and the Rise of Dual-Agonist Drugs

Tirzepatide, sold under the brand names Mounjaro and Zepbound, is the drug that put GIP on the public radar. It is a synthetic peptide that activates both the GIP receptor and the GLP-1 receptor. Its structure is built on the native GIP sequence, with modifications that extend its half-life to about five days, allowing once-weekly dosing.²¹ Tirzepatide binds the GIP receptor with roughly the same strength as natural GIP but hits the GLP-1 receptor about five times less potently than natural GLP-1. This imbalance turns out to be an advantage: pharmacological studies show that tirzepatide’s weaker GLP-1 receptor engagement produces a biased signaling pattern that favors insulin secretion while reducing some of the side effects associated with strong GLP-1 receptor activation, like receptor internalization and desensitization.²²

In clinical trials for type 2 diabetes, tirzepatide reduced HbA1c (a measure of long-term blood sugar control) by 1.24 to 2.58 percentage points and caused weight loss of 5.4 to 11.7 kilograms, depending on dose, results that exceeded what any single-agent drug had achieved before.²³ The success of tirzepatide forced a rethinking of GIP’s therapeutic potential. For decades, the assumption was that GIP’s fat-promoting effects made it a bad target for obesity treatment. Instead, engaging the GIP receptor alongside GLP-1 turned out to amplify weight loss rather than counteract it.

The Paradox of GIP Receptor Agonism and Antagonism

Here is where things get genuinely strange. Both activating and blocking the GIP receptor appear to promote weight loss when combined with GLP-1 receptor stimulation. Several pharmaceutical companies are pursuing GIP receptor antagonist antibodies alongside GLP-1 agonists, and early clinical data support the idea that this combination also produces additive weight loss.²⁴ This is not what anyone expected.

Recent mouse studies have started to untangle the mechanisms behind this paradox. GIP receptor agonism appears to reduce body weight and food intake through a pathway that is independent of GLP-1 signaling, working through specific neurons in the brain. GIP receptor antagonism, on the other hand, depends on a functioning GLP-1 receptor to produce its effects and operates through different neural circuits, with gene-expression changes in the brainstem that actually resemble what GLP-1 receptor activation does.²⁵ In plain terms, turning the GIP receptor on and turning it off both lead to less eating and lower body weight, but by completely different roads through the nervous system. This remains one of the most actively debated puzzles in metabolic pharmacology, and the answer will shape the next generation of obesity drugs.²⁶

How GIP Differs From GLP-1

Because GIP and GLP-1 are so often mentioned together, it is worth knowing where they diverge. Both boost insulin release after a meal, and both promote the growth and survival of beta cells in the pancreas. Beyond that, their job descriptions split apart:

• Glucagon: GIP stimulates glucagon release (especially at low blood sugar), while GLP-1 suppresses it.
• Fat tissue: GIP directly promotes fat storage; GLP-1 has no comparable direct action on adipose tissue.
• Stomach emptying: GLP-1 slows gastric emptying, which helps regulate the rate at which nutrients enter the bloodstream. GIP does not have a significant effect on this.
• Appetite: GLP-1 is a potent satiety signal, and sustained GLP-1 receptor activation drives weight loss. GIP’s appetite effects are more recently discovered and appear to work through partly distinct brain circuits.
• Bone: GIP promotes bone formation and inhibits breakdown. GLP-1 inhibits breakdown but does not directly stimulate new bone growth.

These differences explain why combining the two receptor signals in one drug produces effects that neither could achieve alone.²⁷

An Ancient Hormone With Some Evolutionary Quirks

GIP is not a recent invention of mammalian biology. The gene encoding it diverged very early in vertebrate evolution and is found across most vertebrate classes, from fish to mammals. Its receptor, GIPR, has a similarly ancient origin and belongs to the same family of receptors as those for glucagon, GLP-1, and GLP-2.²⁸ What is curious is that two groups of vertebrates, cartilaginous fish (sharks and rays) and birds, have kept the gene for GIP itself while losing the gene for its receptor. This raises the possibility that GIP signals through alternative receptors in those animals, a question that remains open.²⁹ The loss of GIPR in birds is intriguing given that birds manage blood sugar quite differently from mammals, often running glucose levels that would be considered diabetic in a human. Whether GIP’s absence from bird physiology is related to their unusual glucose tolerance is speculation, but it is the kind of evolutionary loose end that keeps comparative physiologists interested.

GIP in Early Life

GIP is already at work before a baby’s gut is fully mature. In very preterm infants fed fortified human milk, researchers have measured meaningful GIP levels that respond to changes in feeding composition. One study of preterm infants found that those receiving a bovine colostrum-based fortifier had GIP concentrations roughly 20 to 30 percent higher than infants receiving a conventional fortifier shortly after fortification began.³⁰ This suggests that even in the earliest weeks of life, the GIP system is functional and responsive to nutrient signals, and that the composition of what a baby is fed can shift incretin hormone levels in ways that may influence growth and metabolism. Research in this area is still thin, but it opens the door to understanding how early nutrition might program metabolic hormone pathways for the long term.